Author
Prem Kumar with profound experience and sound knowledge across a wide range of market forecasting methods, demand f.....
Bevacizumab Market: By Application, By Distribution Channel, and Geography
Bevacizumab Market size is valued at US$ 8.50 billion in 2023 and is poised to grow at a CAGR of 9.2% from 2024-2030. Bevacizumab, often known as Avastin, is a prescription drug used to treat a variety of tumours and specific eye problems. It is used for colon illness, cellular breakdown in the lungs, glioblastoma, and renal cell carcinoma and is given as a slow infusion into a vein (intravenous). Bevacizumab is used as a first-line treatment for several of these disorders. It is infused into the eye to treat age-related macular degeneration (intravitreal). When used to treat disease, bevacizumab has certain common side effects, including nosebleeds, migraines, hypertension, and dermatitis. Other serious side effects include gastrointestinal bleeding, mortality, negatively susceptible responses, blood clusters, and an increased risk of contamination. When used to treat eye disease, side effects can include vision problems and retinal separation.
Bevacizumab is a monoclonal neutralizer with anti-angiogenesis properties. It acts by slowing the growth of new blood vessels by inhibiting vascular endothelial development factor A (VEGF-A), a major VEGF antagonist. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Bevacizumab Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Bevacizumab Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
2024-2030Base Year
2023CAGR
9.2%Largest Market
North-AmericaFastest Growing Market
Europe
Bevacizumab is a drug that is used to treat a variety of disorders, including colorectal cancer, lung cancer, breast cancer, brain cancer, eye disease, kidney malignancies, cervical and ovarian cancer, and others. During the forecast period, the rising frequency of such diseases would be a major driver boosting the global market's growth. Aside from that, the rising prevalence of age-related macular degeneration is expected to aid market expansion in the future years.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 8.50 billion |
Market CAGR |
9.2% |
By Application |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The global bevacizumab market size was valued at US$8.50 billion in 2023 and is projected to grow at a CAGR of 9.2% from 2024 to 2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Market Players